O	0	1	[
O	1	9	Clinical
O	10	21	comparative
O	22	27	study
O	28	30	of
O	31	42	neoadjuvant
O	43	55	chemotherapy
O	56	63	outcome
O	64	66	in
O	67	74	locally
O	75	83	advanced
O	84	90	breast
O	91	97	cancer
O	97	98	:
B-intervention	99	108	docetaxel
O	109	115	versus
B-control	116	126	paclitaxel
I-control	127	131	plus
I-control	132	143	pirarubicin
I-control	144	157	hydrochloride
I-control	158	161	and
I-control	162	178	cyclophosphamide
O	178	179	]
O	179	180	.

O	181	183	To
O	184	191	compare
O	192	195	the
O	196	204	efficacy
O	205	208	and
O	209	217	toxicity
O	218	220	of
O	221	232	neoadjuvant
O	233	245	chemotherapy
O	246	248	of
O	249	258	docetaxel
O	259	263	with
O	264	274	paclitaxel
O	275	279	plus
O	280	291	pirarubicin
O	292	305	hydrochloride
O	306	307	(
O	307	310	THP
O	310	311	)
O	312	315	and
O	316	332	cyclophosphamide
O	333	334	(
O	334	337	CTX
O	337	338	)
O	339	341	in
B-eligibility	342	349	locally
I-eligibility	350	358	advanced
I-eligibility	359	365	breast
I-eligibility	366	372	cancer
I-eligibility	373	374	(
I-eligibility	374	378	LABC
I-eligibility	378	379	)
O	379	380	.

O	381	382	A
O	383	388	total
O	389	391	of
B-total-participants	392	394	97
O	395	399	LABC
O	400	405	cases
O	406	410	were
O	411	419	randomly
O	420	427	divided
O	428	432	into
O	433	434	2
O	435	441	groups
O	441	442	:
O	443	452	docetaxel
O	453	458	group
O	459	460	(
O	460	461	n
O	462	463	=
B-intervention-participants	464	466	49
O	466	467	,
O	468	476	taxotere
O	477	481	plus
O	482	485	THP
O	486	487	&
O	488	491	CTX
O	491	492	)
O	493	496	and
O	497	507	paclitaxel
O	508	513	group
O	514	515	(
O	515	516	n
O	517	518	=
B-control-participants	519	521	48
O	521	522	,
O	523	533	paclitaxel
O	534	538	plus
O	539	542	THP
O	543	544	&
O	545	548	CTX
O	548	549	)
O	549	550	.

O	551	562	Neoadjuvant
O	563	575	chemotherapy
O	576	579	had
O	580	584	four
O	585	591	cycles
O	592	594	of
O	595	597	21
O	598	602	days
O	603	607	each
O	607	608	.

O	609	612	The
B-outcome	613	621	clinical
O	622	625	and
B-outcome	626	638	pathological
I-outcome	639	647	complete
I-outcome	648	657	remission
I-outcome	658	663	rates
O	664	666	of
O	667	676	docetaxel
O	677	682	group
O	683	686	was
B-iv-bin-percent	687	689	28
I-iv-bin-percent	689	690	.
I-iv-bin-percent	690	691	6
I-iv-bin-percent	691	692	%
O	693	696	and
B-iv-bin-percent	697	699	26
I-iv-bin-percent	699	700	.
I-iv-bin-percent	700	701	5
I-iv-bin-percent	701	702	%
O	703	715	respectively
O	715	716	.

O	717	721	They
O	722	726	were
O	727	740	significantly
O	741	747	higher
O	748	752	than
O	753	758	those
O	759	761	of
O	762	772	paclitaxel
O	773	778	group
O	779	780	(
B-cv-bin-percent	780	782	10
I-cv-bin-percent	782	783	.
I-cv-bin-percent	783	784	4
I-cv-bin-percent	784	785	%
O	786	789	and
B-cv-bin-percent	790	791	8
I-cv-bin-percent	791	792	.
I-cv-bin-percent	792	793	3
I-cv-bin-percent	793	794	%
O	794	795	)
O	795	796	.

O	797	808	Furthermore
O	809	812	the
B-outcome	813	825	pathological
I-outcome	826	834	negative
I-outcome	835	839	rate
I-outcome	840	842	of
I-outcome	843	851	regional
I-outcome	852	857	lymph
I-outcome	858	862	node
O	863	865	in
O	866	875	docetaxel
O	876	881	group
O	882	885	was
O	886	890	also
O	891	904	significantly
O	905	911	higher
O	912	916	than
O	917	921	that
O	922	924	of
O	925	935	paclitaxel
O	936	941	group
O	942	943	(
B-iv-bin-percent	943	945	40
I-iv-bin-percent	945	946	.
I-iv-bin-percent	946	947	6
I-iv-bin-percent	947	948	%
O	949	951	vs
O	951	952	.
B-cv-bin-percent	953	955	12
I-cv-bin-percent	955	956	.
I-cv-bin-percent	956	957	9
I-cv-bin-percent	957	958	%
O	958	959	)
O	959	960	.

O	961	968	However
O	968	969	,
B-outcome	970	975	grade
I-outcome	976	979	III
I-outcome	979	980	-
I-outcome	980	982	IV
I-outcome	983	988	blood
I-outcome	989	995	system
I-outcome	996	1001	toxic
I-outcome	1002	1010	reaction
O	1011	1014	was
O	1015	1020	found
O	1021	1023	in
B-iv-bin-percent	1024	1026	71
I-iv-bin-percent	1026	1027	.
I-iv-bin-percent	1027	1028	4
I-iv-bin-percent	1028	1029	%
O	1030	1035	cases
O	1035	1036	,
B-outcome	1037	1042	grade
I-outcome	1043	1045	II
I-outcome	1045	1046	-
I-outcome	1046	1048	IV
I-outcome	1049	1054	liver
I-outcome	1055	1066	dysfunction
O	1067	1069	in
B-iv-bin-percent	1070	1072	53
I-iv-bin-percent	1072	1073	.
I-iv-bin-percent	1073	1074	1
I-iv-bin-percent	1074	1075	%
O	1076	1081	cases
O	1082	1085	and
B-outcome	1086	1091	edema
O	1092	1094	in
B-iv-bin-percent	1095	1097	24
I-iv-bin-percent	1097	1098	.
I-iv-bin-percent	1098	1099	5
I-iv-bin-percent	1099	1100	%
O	1101	1106	cases
O	1107	1112	among
O	1113	1122	docetaxel
O	1123	1128	group
O	1128	1129	.

O	1130	1134	They
O	1135	1139	were
O	1140	1146	higher
O	1147	1151	than
O	1152	1157	those
O	1158	1163	among
O	1164	1174	paclitaxel
O	1175	1180	group
O	1181	1182	(
B-cv-bin-percent	1182	1184	46
I-cv-bin-percent	1184	1185	.
I-cv-bin-percent	1185	1186	9
I-cv-bin-percent	1186	1187	%
O	1187	1188	,
B-cv-bin-percent	1189	1191	27
I-cv-bin-percent	1191	1192	.
I-cv-bin-percent	1192	1193	1
I-cv-bin-percent	1193	1194	%
O	1195	1196	&
B-cv-bin-percent	1197	1198	4
I-cv-bin-percent	1198	1199	.
I-cv-bin-percent	1199	1200	2
I-cv-bin-percent	1200	1201	%
O	1201	1202	)
O	1202	1203	.

O	1204	1212	Compared
O	1213	1217	with
O	1218	1228	paclitaxel
O	1228	1229	,
O	1230	1233	the
O	1234	1242	combined
O	1243	1250	regimen
O	1251	1253	of
O	1254	1263	docetaxel
O	1264	1268	plus
O	1269	1272	THP
O	1273	1276	and
O	1277	1280	CTX
O	1281	1287	offers
O	1288	1294	better
O	1295	1303	outcomes
O	1304	1307	for
O	1308	1315	locally
O	1316	1324	advanced
O	1325	1331	breast
O	1332	1338	cancer
O	1338	1339	.
